V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Cytokinetics Executive Compensation (FY25)

CYTK · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Robert Blum
Latest say-on-pay support
=
May 27, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Cytokinetics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 20, 2026Latest filing (8-K): May 27, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Cytokinetics brief$1,500Get the executive brief
Velarion Member, one year
274 figures on this page: 268 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

More on Cytokinetics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Say-on-pay support: 95.5% → 97.2% (1.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Cytokinetics' chief executive and what were they paid?
Robert Blum was paid $11,881,456 in total compensation as President and Chief Executive Officer for fiscal 2025.
What was Cytokinetics' say-on-pay result?
The say-on-pay proposal drew 97.2% of votes cast for or against in favor at the meeting held May 27, 2026 for fiscal 2025.
Which companies are in Cytokinetics' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc. and Ascendis Pharma A/S, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Blum
Principal Executive Officer
◇—◇◇◇—◇◇
Fady Malik
Executive Vice President, Research and Development
◇—◇◇◇—◇◇
Ching Jaw
Principal Financial Officer
◇—◇◇◇—◇◇
Andrew Callos
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
David W. Cragg
Senior Vice President, Chief Human Resources and Administration Officer
◇—◇◇——◇◇
Mark A. Schlossberg
Senior Vice President, Legal and General Counsel and Secretary
◇—◇◇———◇
Robert Wong
Vice President, Chief Accounting Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Blum
Principal Executive Officer
◇—◇◇◇—◇◇
Fady Malik
Executive Vice President, Research and Development
◇—◇◇◇—◇◇
Andrew Callos
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Ching Jaw
Former Senior Vice President, Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Robert Wong
Vice President, Chief Accounting Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Blum
President and Chief Executive Officer
◇—◇◇◇—◇— not reconciled
Sung Lee
Executive Vice President, Chief Financial Officer
◇◇◇◇◇—◇— not reconciled
Brett Pletcher
Former Executive Vice President and Chief Legal Officer
Departed during or after this year
◇◇◇◇◇——◇
Fady Malik
Executive Vice President, Research and Development
◇—◇◇◇—◇◇
Andrew Callos
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Ching Jaw
Former Senior Vice President, Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Blum
President and Chief Executive Officer
◇—◇◇◇—◇◇
Jeffrey Hessekiel
Executive Vice President, Chief Legal and Administrative Officer
◇◇◇———◇◇
Fady Malik
Executive Vice President, Research and Development
◇—◇◇◇—◇◇
Andrew Callos
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Sung Lee
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew M. CallosRSU◇——◇——◇
Andrew M. CallosOPTION◇——◇—◇◇
Fady I. MalikRSU◇——◇——◇
Fady I. MalikOPTION◇——◇—◇◇
Jeffrey HessekielRSU◇——◇——◇
Robert I. BlumRSU◇——◇——◇
Robert I. BlumOPTION◇——◇—◇◇
Sung H. LeeRSU◇——◇——◇
Sung H. LeeOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sung LeeRSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Andrew CallosRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Robert BlumOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Jeffrey HessekielRSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert E. Landry
◇◇◇———◇
Robert E. Daly
◇—◇———◇
B. Lynne Parshall
◇◇◇———◇
Fiona Bhanji
◇◇◇———◇
Wendell Wierenga
◇◇◇———◇
Nancy J. Wysenski
◇◇◇———◇
John T. Henderson
◇◇◇———◇
Edward M. Kaye
◇◇◇———◇
Robert A. Harrington
◇◇◇———◇
Robert I. Blum served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options.
Stock ownership guideline: 3x annual cash retainer (committee retainers excluded) for non-executive directors

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Ascendis Pharma A/S ASND
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corporation BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Denali Therapeutics Inc. DNLI
  • Halozyme Therapeutics, Inc. HALO
  • ImmunityBio, Inc. IBRX
  • Immunovant, Inc. IMVT
  • INSMED Inc. INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Legend Biotech Corp LEGN
  • Madrigal Pharmaceuticals, Inc. MDGL
  • Sarepta Therapeutics, Inc. SRPT
  • Ultragenyx Pharmaceuticals Inc. RARE
  • Vaxcyte, Inc. PCVX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 27, 2026=◇◇◇
2024May 14, 2025=◇◇◇
2023May 15, 2024=◇◇◇
2022May 10, 2023=◇◇◇
2021May 10, 2022=◇◇◇
2020May 12, 2021=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Blum (President and Chief Executive Officer), FY2025 total compensation $11,881,456 (base salary $853,069) [exec_comp, SEC accession 0001140361-26-015364, filed 2026-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Cytokinetics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Cytokinetics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cytokinetics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Cytokinetics' disclosed peer group is defensible, who names Cytokinetics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
274 figures on this page: 268 cited to the filing that reported them, 6 calculated from figures it prints.
268 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-241840
  2. 0001140361-26-015364
    Director Compensation · Director Compensation Table for 2025 · Executive Summary Compensation Table for 2025 · Grants of Plan-Based Awards in 2025 · and 1 more section
  3. 0000950170-25-072965
  4. 0001140361-25-013167
    Executive Summary Compensation Table for 2024
  5. 0000950170-24-061275
  6. 0001140361-24-018628
    Executive Summary Compensation Table for 2023
  7. 0000950170-23-020843
  8. 0001140361-23-017329
    Executive Summary Compensation Table for 2022
  9. 0001171843-22-003569
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001171843-21-003496
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cytokinetics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CYTK (accessed 2026).
Short form: data: Velarion

The paid brief for Cytokinetics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cytokinetics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Cytokinetics discloses

The companies named in CYTK's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.Axsome Therapeutics, Inc.Blueprint Medicines CorporationBridgeBio Pharma, Inc.Crinetics Pharmaceuticals, Inc.Denali Therapeutics Inc.Halozyme Therapeutics, Inc.ImmunityBio, Inc.Immunovant, Inc.INSMED Inc.Intra-Cellular Therapies, Inc.Ionis Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.Ultragenyx Pharmaceuticals Inc.Vaxcyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy